Study of Enavogliflozin for Type 2 Diabetes with High Blood Pressure or High Cholesterol
Part of Hormones & metabolism clinical trials.
This study looks at how well a medication called Enavogliflozin works for people with type 2 diabetes who also have high blood pressure or high cholesterol. It aims to see if the drug is safe and effective when taken as part of routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have type 2 diabetes along with high blood pressure or high cholesterol.
- You are already taking or about to start taking Envlo Tab or Envlomet SR Tab.
- You are willing to follow the study rules and give your written consent.
- Your kidneys work well enough (eGFR is 60 or higher).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This trial tests if Enavogliflozin, a medication for diabetes, can improve blood flow in the small vessels of the heart and overall heart function in people with obesity or diabetes. You may join if you have obesity or diabetes and have had a recent heart test.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
This trial studies whether dapagliflozin (the medicine in Trudapa tabs) is safe and works in people who have both type 2 diabetes and high blood pressure. It may help control blood sugar and blood pressure, while researchers closely watch for side effects.
This study tests a drug called enavogliflozin to see if it helps people with a specific type of heart failure caused by amyloid buildup. It may improve symptoms and daily function.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.